“If you're going to try to embrace new worlds, you must try to embrace new ideas."

genetic heart diseases

genetic heart diseases

genetic heart diseases

genetic heart diseases

SEO related. Do not remove this box.
Phlox Therapeutics pioneers gene therapy to alleviate and cure different heart diseases. By embracing new ideas, we want to change the world for patients to whom the current standard of care falls short. Current treatment often barely addresses symptoms and cannot halt the progression of the disease as it fails to target the underlying causes. Imagine the possibilities of our approach. We envision a world where our technology can cure genetic heart diseases, providing lifelong benefit to patients and their relatives. 
Cardiac dysfunction is the leading cause of death world-wide. Our ultimate goal is to cure genetic heart disease. Therefore, we develop a new class of potent precision genetic medicines. 

Latest News

Phlox Therapeutics Raises Additional Seed Funding to Further Develop RNA Therapies for Genetic Laminopathies

Phlox Therapeutics raises additional seed funding to develop RNA therapies for genetic laminopathies Funds will advance the company’s lead program into preclinical development 9 May 2023, Naarden, The Netherlands – Phlox Therapeutics (“Phlox”), a private biotechnology company specializing in developing innovative RNA-therapeutics for rare genetic cardiomyopathies, has secured additional seed funding to advance Phlox’s lead […]
continue reading

Phlox Therapeutics closes seed investment round

Company’s technology set to revolutionize the treatment of genetic cardiovascular diseases through its development of RNA-based therapeutics May 2020, Naarden, The Netherlands – Phlox Therapeutics, a biotech spin-off of the Amsterdam University Medical Center founded by prof. dr. Yigal Pinto and prof. dr. Eva van Rooij, with Margien Boels, PhD as it’s initiating director of operations […]
continue reading

Investors

logo image of F1RST Biogeneration Ventures

Team

Prof. dr. Yigal Pinto

Founder and CMO

Margien Boels

Director of Operations

Prof. dr. Eva Van Rooij

Founder and CSO

Rianne Ellenbroek

Non-executive director

Ross Gordon 

Observer

“If you're going to try to embrace new worlds, you must try to embrace new ideas."

Phlox Therapeutics pioneers gene therapy to alleviate and cure different heart diseases. By embracing new ideas, we want to change the world for patients to whom the current standard of care falls short. Current treatment often barely addresses symptoms and cannot halt the progression of the disease as it fails to target the underlying causes. Imagine the possibilities of our approach. We envision a world where our technology can cure genetic heart diseases, providing lifelong benefit to patients and their relatives. 

Cardiac dysfunction is the leading cause of death world-wide. Our ultimate goal is to cure genetic heart disease. Therefore, we develop a new class of potent precision genetic medicines.

Latest news

Phlox Therapeutics Raises Additional Seed Funding to Further Develop RNA Therapies for Genetic Laminopathies

Phlox Therapeutics raises additional seed funding to develop RNA therapies for genetic laminopathies Funds will advance the company’s lead program into preclinical development 9 May 2023, Naarden, The Netherlands – Phlox Therapeutics (“Phlox”), a private biotechnology company specializing in developing innovative RNA-therapeutics for rare genetic cardiomyopathies, has secured additional seed funding to advance Phlox’s lead […]
continue reading

Phlox Therapeutics closes seed investment round

Company’s technology set to revolutionize the treatment of genetic cardiovascular diseases through its development of RNA-based therapeutics May 2020, Naarden, The Netherlands – Phlox Therapeutics, a biotech spin-off of the Amsterdam University Medical Center founded by prof. dr. Yigal Pinto and prof. dr. Eva van Rooij, with Margien Boels, PhD as it’s initiating director of operations […]
continue reading

Investors

logo image of F1RST Biogeneration Ventures

Team

Prof. dr. Yigal Pinto
Founder and CMO
Margien Boels
Director of Operations
Prof. dr. Eva Van Rooij
Founder and CSO
Rianne Ellenbroek
Non-executive director
Ros Gordon
Observer